No Data
No Data
Sinopharm Unveils Current Board Structure and Roles
Sinopharm Group EGM: Directors Approved, Auditors Appointed
Sinopharm's early trading rose more than 4%, the company's pharmaceutical distribution business may show steady growth in the second half of the year.
Sinopharm (01099) rose 4.28% in early trading, now at HKD 17.06, with a turnover of HKD 84.975 million. Sinopharm previously released its mid-year performance, achieving revenue of CNY 294.727 billion in the first half of the year, a year-on-year decrease of 2.07%, and a net income attributable to the parent company of CNY 3.704 billion, a year-on-year decrease of 9.76%.
Hong Kong stocks rise | Sinopharm (01099) rose more than 5% in early trading, pharmaceutical distribution business is expected to grow steadily in the second half of the year, and medical device distribution business is expected to improve compared to the
Sinopharm (01099) rose more than 5% in early trading. As of the time of writing, it has increased by 4.4%, reaching HKD 17.08 with a turnover of HKD 80.6915 million.
China Securities Co., Ltd. maintains a "buy" rating on Sinopharm (01099), and expects the medical device distribution business to improve compared to the previous year in the second half of the year.
China Securities Co., Ltd. released a research report stating that sinopharm (01099) has released its 2024 semi-annual performance report. In the first half of 2024, the company achieved revenue of 294.727 billion yuan, a year-on-year decrease of 2.07%, and achieved a net income of 3.704 billion yuan attributable to the parent, a year-on-year decrease of 9.76%. The performance was lower than expected, mainly due to pressure on the medical device distribution business. The bank pointed out that in the second half of the year, the impact of compliant sales in hospitals is expected to stabilize, the pharmaceutical distribution business may maintain steady growth, and the replacement of medical devices is expected to release incremental growth. The distribution business of medical devices is expected to improve on a month-on-month basis, with the company continuing to focus on building.
With a compound annual growth rate of only 2.6% over the past five years, China's top 100 pharmaceutical companies are entering an adjustment period. How will the industry break through under internal and external pressures?
According to the data from China Meheco Group, in 2023, multiple operation indicators of the pharmaceutical industry's leading companies have declined. The compound annual growth rate of the top 100 pharmaceutical companies in the country in the past five years is only 2.6%, and the industry as a whole has entered the adjustment phase from the initial high-speed growth. Behind the weak growth, the health industry is also undergoing transformation: overseas licensing trades for innovative drugs have reached a new high, and leading companies are accelerating outward expansion...
No Data
No Data